These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 24510638)

  • 1. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    Silber S; Kirtane AJ; Belardi JA; Liu M; Brar S; Rothman M; Windecker S
    Eur Heart J; 2014 Aug; 35(29):1949-56. PubMed ID: 24510638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study.
    Zhang YJ; Zhao YL; Xu B; Han YL; Li B; Liu Q; Su X; Pang S; Lu SZ; Guo XF; Yang YJ
    Chin Med J (Engl); 2015 Mar; 128(6):714-20. PubMed ID: 25758261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).
    Kim BK; Hong MK; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Kang TS; Park BE; Kang WC; Lee SH; Yoon JH; Hong BK; Kwon HM; Jang Y;
    J Am Coll Cardiol; 2012 Oct; 60(15):1340-8. PubMed ID: 22999717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.
    Tandjung K; Sen H; Lam MK; Basalus MWZ; Louwerenburg JHW; Stoel MG; van Houwelingen KG; de Man FHAF; Linssen GCM; Saïd SAM; Nienhuis MB; Löwik MM; Verhorst PMJ; van der Palen J; von Birgelen C
    J Am Coll Cardiol; 2013 Jun; 61(24):2406-2416. PubMed ID: 23602769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program.
    Yeh RW; Silber S; Chen L; Chen S; Hiremath S; Neumann FJ; Qiao S; Saito S; Xu B; Yang Y; Mauri L
    JACC Cardiovasc Interv; 2017 Feb; 10(3):247-254. PubMed ID: 28109872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors.
    Lee SY; Hong MK; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Kim HS; Valgimigli M; Palmerini T; Stone GW
    Clin Res Cardiol; 2017 Mar; 106(3):165-173. PubMed ID: 27631821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
    Hahn JY; Song YB; Choi JH; Choi SH; Lee SY; Park HS; Hur SH; Lee S; Han KR; Rha SW; Cho BR; Park JS; Yoon J; Lim DS; Lee SH; Gwon HC;
    Circ J; 2010 Nov; 74(11):2314-21. PubMed ID: 20938098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial.
    Lee JM; Cho DK; Hahn JY; Song YB; Park TK; Oh JH; Lee JB; Doh JH; Kim SH; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC
    Am Heart J; 2016 Dec; 182():1-8. PubMed ID: 27914488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy.
    Cutlip DE; Kereiakes DJ; Mauri L; Stoler R; Dauerman HL;
    JACC Cardiovasc Interv; 2015 Mar; 8(3):404-410. PubMed ID: 25703885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".
    Kedhi E; Fabris E; van der Ent M; Kennedy MW; Buszman P; von Birgelen C; Cook S; Wedel H; Zijlstra F
    Am Heart J; 2017 Jun; 188():11-17. PubMed ID: 28577666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
    Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
    Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of dual antiplatelet therapy after various drug-eluting stent implantation.
    Sharma A; Sharma SK; Vallakati A; Garg A; Lavie CJ; Mukherjee D; Marmur JD
    Int J Cardiol; 2016 Jul; 215():157-66. PubMed ID: 27116326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the 9-month intra-stent conditions and 2-year clinical outcomes after Resolute zotarolimus-eluting stent implantation between 3-month and standard dual antiplatelet therapy.
    Fujimoto W; Sawada T; Toba T; Takahashi Y; Miyata T; Oishi S; Osue T; Onishi T; Takaya T; Shimane A; Taniguchi Y; Kawai H; Yasaka Y
    J Cardiol; 2018 Jul; 72(1):66-73. PubMed ID: 29456058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
    Kim BK; Hong SJ; Cho YH; Yun KH; Kim YH; Suh Y; Cho JY; Her AY; Cho S; Jeon DW; Yoo SY; Cho DK; Hong BK; Kwon H; Ahn CM; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y;
    JAMA; 2020 Jun; 323(23):2407-2416. PubMed ID: 32543684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes with 6 months dual antiplatelet therapy after implantation of biolimus-A9 drug eluting coronary stents.
    Cockburn J; Pareek N; Poliacikova P; Saraf S; Williams R; Dhillon G; Robinson D; Gerber R; Hatrick R; Blows L; de Belder A; Hildick-Smith D
    Int J Cardiol; 2014 Mar; 172(1):185-9. PubMed ID: 24462139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy)-diabetes substudy.
    Tarantini G; Nai Fovino L; Tellaroli P; Chieffo A; Barioli A; Menozzi A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Dominguez JF; Steffanon L; Presbitero P; Pucci E; Fraccaro C; Mauri J; Giustino G; Sardella G; Colombo A
    Int J Cardiol; 2016 Mar; 207():168-76. PubMed ID: 26803236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 Trial.
    Han Y; Xu B; Xu K; Guan C; Jing Q; Zheng Q; Li X; Zhao X; Wang H; Zhao X; Li X; Yu P; Zang H; Wang Z; Cao X; Zhang J; Pang W; Li J; Yang Y; Dangas GD
    Circ Cardiovasc Interv; 2016 Feb; 9(2):e003145. PubMed ID: 26858080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial.
    Natsuaki M; Morimoto T; Yamamoto E; Shiomi H; Furukawa Y; Abe M; Nakao K; Ishikawa T; Kawai K; Yunoki K; Shimizu S; Akao M; Miki S; Yamamoto M; Okada H; Hoshino K; Kadota K; Morino Y; Igarashi K; Tanabe K; Kozuma K; Kimura T
    Cardiovasc Interv Ther; 2016 Jul; 31(3):196-209. PubMed ID: 26518420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
    Youn YJ; Lee JW; Ahn SG; Lee SH; Choi H; Yu CW; Hong YJ; Kwon HM; Hong MK; Jang Y; Yoon J
    Am Heart J; 2014 Feb; 167(2):241-248.e1. PubMed ID: 24439986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.